Alpha 1 Antitrypsin Deficiency Treatment

Alpha 1 Antitrypsin Deficiency Treatment

Global Alpha 1 Antitrypsin Deficiency Treatment Market to Reach US$4.2 Billion by 2030

The global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$2.3 Billion in the year 2023, is expected to reach US$4.2 Billion by 2030, growing at a CAGR of 9.0% over the analysis period 2023-2030. Augmentation Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Bronchodilator segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$638.8 Million While China is Forecast to Grow at 8.2% CAGR

The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$638.8 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$635.0 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.3% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global Alpha 1 Antitrypsin Deficiency Treatment Market - Key Trends & Drivers Summarized

What Is Alpha 1 Antitrypsin Deficiency and Why Is It Important?

Alpha 1 Antitrypsin Deficiency (AATD) is a genetic disorder that affects the lungs and liver, caused by insufficient levels of the protein alpha 1 antitrypsin (AAT), which protects tissues from enzyme damage. The deficiency can lead to chronic obstructive pulmonary disease (COPD), emphysema, and liver diseases like cirrhosis. AATD is underdiagnosed, and many patients suffer from symptoms for years before receiving appropriate treatment. Managing the condition often requires augmentation therapy, where patients are given purified AAT to reduce lung damage and prevent further deterioration.

What Recent Advancements Are Improving Alpha 1 Antitrypsin Deficiency Treatments?

Recent advancements in the treatment of Alpha 1 Antitrypsin Deficiency include the development of new augmentation therapies and research into gene therapies aimed at correcting the underlying genetic cause. Augmentation therapy, which involves intravenous administration of purified AAT derived from human plasma, remains the primary treatment option for AATD. However, researchers are now focusing on more advanced therapeutic approaches such as RNA-based therapies, which aim to correct the faulty gene responsible for AATD. These developments are creating more effective and long-term solutions for patients, potentially reducing the need for lifelong augmentation therapy.

How Is Awareness and Diagnosis Impacting AATD Treatment Trends?

One of the key challenges in treating Alpha 1 Antitrypsin Deficiency is the high rate of underdiagnosis. Increased awareness campaigns by healthcare organizations and patient advocacy groups are gradually improving diagnosis rates, leading to earlier intervention and better outcomes for patients. Genetic testing has also become more widely available, allowing individuals with a family history of AATD to be screened and diagnosed earlier. As awareness of AATD grows, more patients are gaining access to life-saving treatments, particularly in developed healthcare markets.

What Factors Are Driving the Growth of the Alpha 1 Antitrypsin Deficiency Treatment Market?

The growth in the Alpha 1 Antitrypsin Deficiency treatment market is driven by several factors, including advancements in gene and augmentation therapies, improved diagnosis rates, and increasing awareness of the condition. Innovations in augmentation therapy and research into genetic correction methods are making treatments more effective and accessible. The growing availability of genetic testing is also helping in early detection and treatment, significantly improving patient outcomes. Moreover, patient advocacy and education campaigns are raising awareness about the disorder, prompting earlier intervention and driving demand for AATD therapies.

Select Competitors (Total 46 Featured) -

• Abeona Therapeutics Inc.
• Applied Genetic Technologies Corporation
• Arrowhead Pharmaceuticals Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Chiesi Farmaceutici SpA
• CSL Behring
• Curaxys
• GlaxoSmithKline PLC
• Grifols International SA
• Kamada Ltd.
• Pfizer, Inc.
• ProBioGen AG
• ProMetic Life Sciences, Inc.
• Shire PLC
• Teva Pharmaceutical Industries Ltd.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.